+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction



Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction



Cardiology in Review 20(6): 319-324



Periprocedural myocardial infarction (PMI) is a common complication associated with percutaneous coronary intervention (PCI), occurring in approximately 15% to 20% of patients undergoing the procedure. The established diagnostic criteria for PMI is an increase in cardiac biomarkers, specifically creatine kinase-MB levels > 3 times the upper limit of normal. As PMI has been associated with an increased risk of mortality after PCI, investigative efforts have been directed at therapies that can potentially decrease PMI. One such therapy is the use of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) administered as a loading dose before PCI. Multiple small, randomized, controlled trials have demonstrated significant reductions in the incidence of PMI with statin loading before PCI. The risk reduction was seen in patients with stable and unstable coronary artery disease, as well in statin-naive patients or those on chronic statin therapy. Potential mechanisms for the rapid benefits of statin loading include: anti-inflammatory effects, reversal of endothelial dysfunction, decrease in oxidative stress, and inhibition of the thrombotic system. None of the current studies were of sufficient power or duration to detect benefits on mortality, though a recent meta-analysis did demonstrate a reduction in major adverse cardiovascular events. In addition to long-term effects, several additional questions remain with regard to statin loading, such as statin type, dose, and optimal timing of administration. However, given the current evidence of benefit and the low risk of adverse events, it can be recommended that all patients undergoing PCI be considered for statin loading before the procedure.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911111

Download citation: RISBibTeXText

PMID: 22874885

DOI: 10.1097/CRD.0b013e31826db7ff


Related references

Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. European Heart Journal 25(20): 1822-1828, 2004

Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Acc Current Journal Review 14(2): 45-0, 2005

High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 3-day major cardiac adverse events. Evidence-Based Medicine 17(1): 13-14, 2012

Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?. Current Medical Research and Opinion 30(3): 381-386, 2014

Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. International Journal of Cardiology 168(3): 2494-2497, 2014

Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis. Clinical Cardiology 38(11): 668-678, 2016

High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. Plos One 9(12): E113352, 2015

Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. Jacc. Cardiovascular Interventions 3(3): 332-339, 2010

Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. American Journal of Cardiology 94(11): 1363-1366, 2004

Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coronary Artery Disease 22(1): 87-91, 2011

Impact of coronary plaque burden and composition on periprocedural myocardial infarction and coronary flow reserve after percutaneous coronary intervention. International Heart Journal 55(5): 391-396, 2014

Impact on prognosis of periprocedural myocardial infarction after percutaneous coronary intervention. Journal of Interventional Cardiology 27(5): 482-490, 2016

Coronary plaque morphology on multi-modality imagining and periprocedural myocardial infarction after percutaneous coronary intervention. International Journal of Cardiology. Heart and Vasculature 11: 43-48, 2016

Detecting Periprocedural Myocardial Infarction in Contemporary Percutaneous Coronary Intervention Trials. Jacc. Cardiovascular Interventions 10(7): 658-666, 2017

Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina. Journal of Cardiology 62(2): 77-81, 2014